Tetrahydroanthraquinone Derivative (±)-4-Deoxyaustrocortilutein Induces Cell Cycle Arrest and Apoptosis in Melanoma Cells via Upregulation of p21 and p53 and Downregulation of NF-kappaB

Abstract

Background: Malignant melanoma is an aggressive type of skin cancer with high risk for metastasis and chemoresistance. Disruption of tightly regulated processes such as cell cycle, cell adhesion, cell differentiation and cell death are predominant in melanoma development. So far, conventional treatment options have been insufficient to treat metastatic melanoma and survival rates are poor. Anthraquinone compounds have been reported to have anti-tumorigenic potential by DNA-interaction, promotion of apoptosis and suppression of proliferation in various cancer cells.Methods: In the current study, the racemic tetrahydroanthraquinone derivative (±)-4-deoxyaustrocortilutein (4-DACL) was synthesized and the cytotoxic activity against melanoma cells and melanoma spheroids determined by CellTiter-Blue viability Assay and phase contrast microscopy. Generation of reactive oxygen species (ROS) was determined with CellROX Green and Deep Red Reagent kit and microplate-based fluorometry. Luciferase reporter gene assays for nuclear factor kappa B (NF-κB) and p53 activities and western blotting analysis were carried out to detect the expression of anti-proliferative or pro-apoptotic (p53, p21, p27, MDM2, and GADD45M) and anti-apoptotic (p65, IκB-α, IKK) proteins. Cell cycle distribution and apoptosis rate were detected by flow cytometry, the morphological changes visualized by fluorescence microscopy and the activation of different caspase cascades distinguished by Caspase Glo 3/7, 8 and 9 Assays.Results: We demonstrated that 4-DACL displayed high activity against different malignant melanoma cells and melanoma spheroids and only low toxicity to melanocytes and other primary cells. In particular, 4-DACL treatment induced mitochondrial ROS, reduced NF-κB signaling activity and increased up-regulation of the cell cycle inhibitors cyclin-dependent kinase inhibitor p21 (p21WAF1/Cip1) and the tumor suppressor protein p53 in a dose-dependent manner, which was accompanied by decreased cell proliferation and apoptosis via the intrinsic pathway.Conclusion: According to these results, we suggest that 4-DACL may be a promising therapeutic agent for the treatment of malignant melanoma.

Nrf2 promotes oesophageal cancer cell proliferation via metabolic reprogramming and detoxification of reactive oxygen species

“…To assess Nrf2‐mediated ROS detoxification, we examined the effect of Nrf2 depletion on the production of ROS. We used the CellROX Green Reagent, which can detect ROS in nuclei and mitochondria because ROS generated by mitochondria move to the nucleus and participate in various signalling pathways in cancer cells . In our analysis, ROS were detected in the nucleus in TE‐11 (supplementary material, Figure S5A).…”

Autophagy: In the cROSshairs of cancer

“…In addition to Elesclomol, there is overwhelming support for pharmacological redox modulation as a viable therapeutic target across cancer subtypes. Specifically, we highlight recent studies in which pharmacological redox modulation results in melanoma cell apoptosis, summarized in Table 1 [20, 29-33]. …”

Antitumorigenic effect of damnacanthal on melanoma cell viability through p53 and NF‑κB/caspase‑3 signaling pathways

“…Tumor protein p53 (p53) is the tumor suppressor gene which has been most widely associated with human tumors (5). Under normal circumstances, p53 functions in DNA repair and replication, arresting cell proliferation following DNA damage, which inhibits tumor growth (6).…”

“…High expression of p53 protein indicates a mutation of p53. p53 has been demonstrated to serve an important function in the occurrence and development of melanoma (5).…”